Novo Nordisk -14% after forecasting a 5% to 13% sales drop in 2026 and a 14% Q4 profit decline

Source: [ https://finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html ](https://finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html)

Shares of obesity drugmakers and developers slid on Tuesday after Novo ​Nordisk forecast a sharper-than-expected sales decline ‌for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

Eli ‌Lilly was down about 4%, Structure Therapeutics fell 6.2%, while Altimmune dropped 4.2%. Viking Therapeutics declined more than 3% and Amgen slipped nearly 1% ⁠in afternoon trading.

The ‌Danish drugmaker said it expects sales to drop between 5% and 13% ‍this year, compared with analysts' average expectation of a 2% decline. Its U.S.-listed shares fell 13.8% to $50.83.

Wegovy-maker ​Novo also reported a 14% fall in ‌fourth-quarter operating profit to 31.7 billion Danish crowns, slightly above the estimate of 31.2 billion crowns.

The selloff comes as Wall Street is reassessing long-held expectations that the obesity drug market could ⁠hit $150 billion early next decade, ​as U.S. prices for GLP-1 ​treatments from Novo and Lilly fall sharply and competition intensifies in the cash-pay ‍consumer market.

Analysts ⁠have pushed out peak sales timelines and trimmed forecasts, with some now seeing the ⁠market closer to $80 billion to $105 billion by 2030.